APA

Jabbour E., Hochhaus A., Cortes J., La Rosée P. & Kantarjian H. M. (20100127). Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. : Leukemia.

Chicago

Jabbour E, Hochhaus A, Cortes J, La Rosée P and Kantarjian H M. 20100127. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. : Leukemia.

Harvard

Jabbour E., Hochhaus A., Cortes J., La Rosée P. and Kantarjian H. M. (20100127). Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. : Leukemia.

MLA

Jabbour E, Hochhaus A, Cortes J, La Rosée P and Kantarjian H M. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. : Leukemia. 20100127.